Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Withdrawn Phase 1 Trials for Rivogenlecleucel (DB19107)
| Indication | Status | Phase |
|---|---|---|
| DBCOND0115568 (Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm) | Withdrawn | 1 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT03807063 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant | Treatment |